Amenavir Tablet

Herpes simplex, herpes zoster

Adult Oral Herpes simplex: The usual adult dosage of Amenavir is 200 mg administered orally once daily after meal. Recurrent herpes simplex: 1200 mg single dose after meals within 6 hours after the appearance of the initial symptoms of recurrent herpes simplex. (Only one dose is required). Herpes zoster: The usual adult dosage of Amenavir is 400 mg administered orally once daily after meal.

Renal Impairment Mild to Moderate (eGFR ? 30 mL/min/1.73 m²): No dose adjustment required. Severe (eGFR < 30 mL/min/1.73 m²): Limited data; exposure may increase — use with caution and monitor renal function. End-Stage Renal Disease / Dialysis: Not studied; avoid use or use only if benefits outweigh potential risk.

Hepatic Impairment Mild to Moderate (Child–Pugh A or B): No significant pharmacokinetic changes; no adjustment usually needed. Severe (Child–Pugh C): Data unavailable; use cautiously or consider alternatives.

Known hypersensitivity or allergy to amenamevir or any of its components. Severe Renal Impairment.

Hepatic or renal impairment: Limited clinical data; use with caution and monitor function. Special monitoring is essential for patients with the following clinical conditions: Severe renal impairment Thrombocytopenia Elderly patients

Not Classi Pregnancy: Insufficient human data; use only if potential benefit justifies possible risk. Lactation: Limited data; small transfer into breast milk reported (estimated RID < 10%).

Amenavir has notable interactions with certain drugs due to its metabolism via cytochrome P450 enzymes, particularly CYP3A4. Ketoconazole: As a strong CYP3A4 inhibitor, Ketoconazole significantly increases the plasma concentration of Amenavir. Rifampicin:This strong CYP3A4 inducer markedly decreases Amenavir levels, that could lead to reduced efficacy of Amenavir. Midazolam: As a substrate of CYP3A4, Midazolam's pharmacokinetics are affected by Amenavir, leading to decreased plasma levels when both are taken together. Warfarin: No significant interaction was observed between Amenavir and Warfarin, a medication metabolized by CYP2C9. Live viral vaccines: May reduce vaccine efficacy; concurrent use not recommended. Caution with drugs affecting hepatic metabolism or renal excretion.

Common: Nausea, diarrhea, headache, nasopharyngitis, sore throat. Uncommon/Post-marketing: Thrombocytopenia, gingival bleeding, palpitations.

Helicase-Primase Inhibitor: Blocks the helicase-primase complex essential for viral DNA replication in HSV and VZV, inhibiting viral genome synthesis and replication.

Amenavir 200 mg Tablet manufactured by Square Pharmaceuticals PLC.. Its generic name is Amenamevir.